<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33602017</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>sup1</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Clinical care and therapeutic trials in PLS.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>73</EndPage><MedlinePgn>67-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1837180</ELocationID><Abstract><AbstractText>Primary lateral sclerosis (PLS) is an extremely rare central nervous system degenerative disorder characterized by slowly progressive upper motor neuron loss leading to severe limb and bulbar dysfunction and disability. Although not necessarily life-shortening, PLS disease burden is substantial and improved symptomatic treatments are a major unmet need, especially for the often refractory spasticity that is a core feature of the syndrome. In Section 1, we describe clinical care needs and emphasize a highly personalized approach that can be best attained through multidisciplinary management. In Section 2, we describe progress in clinical trials in PLS that includes advances in symptomatic treatment, disease-modifying therapy, and emerging innovative trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Floeter</LastName><ForeName>Mary Kay</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warden</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Dale</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital for Special Surgery, Weill Cornell School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at Mass General, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R13 NS111790</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009128" MajorTopicYN="N">Muscle Spasticity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Care and management</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">PLS</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Supplement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>19</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33602017</ArticleId><ArticleId IdType="mid">NIHMS1664563</ArticleId><ArticleId IdType="pmc">PMC7899088</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1837180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66(5):647&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain. 1992;115 (Pt 2):495&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">1606479</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiat. 2020; 91(4):373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147236</ArticleId><ArticleId IdType="pubmed">32029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Chiuzan C, Gilmore M, Zhang Y, Simmons Z, Paganoni S, et al. Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. Muscle Nerve. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31758557</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Wu T. Longitudinal evaluation of upper motor neuron burden scales in primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935469</ArticleId><ArticleId IdType="pubmed">32657626</ArticleId></ArticleIdList></Reference><Reference><Citation>Spastic Paraplegia Foundation, Inc. Spastic Paraplegia Foundation. https://sp-foundation.org.
Accessed
12/13/2020.</Citation></Reference><Reference><Citation>National Center for Complimentary and Integrative Health. https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name.
Accessed
7/21/2020.</Citation></Reference><Reference><Citation>Goyal M, Singh S, Sibinga EM, Gould NF, Rowland-Seymour A, Sharma R, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142584</ArticleId><ArticleId IdType="pubmed">24395196</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvard University. Undiagnosed Diseases Network. https://undiagnosed.hms.harvard.edu/.
Accessed
12/13/2020.</Citation></Reference><Reference><Citation>Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, et al. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med. 2018;54(4):605&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">29265792</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H. Primary Lateral Sclerosis. Neurol Clin. 2015;33(4):749&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628724</ArticleId><ArticleId IdType="pubmed">26515619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Haas VD, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007;68(23):2003&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548549</ArticleId></ArticleIdList></Reference><Reference><Citation>Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, et al. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):250&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191052</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Zhang W, Kang L, Ma Y, Fu L, Jia L, et al. Clinical Evidence of Exercise Benefits for Stroke. Adv Exp Med Biol. 2017;1000:131&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">29098620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">3887172</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849173</ArticleId><ArticleId IdType="pubmed">24348042</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256051</ArticleId><ArticleId IdType="pubmed">30152872</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn D
Schoolin&#x2019; Google in ALS
2019.  [Available from: https://alsnewstoday.com/2019/01/29/google-dysarthria-als-speech-recognition/.</Citation></Reference><Reference><Citation>Medicine USNLo. Use of Dalfampridin in Primary Lateral Sclerosis
2019.  [Available from: https://clinicaltrials.gov/ct2/show/NCT02868567?term=NCT02868567&amp;draw=2&amp;rank=1.</Citation></Reference><Reference><Citation>Behrman AL, Ardolino EM, Harkema SJ. Activity-Based Therapy: From Basic Science to Clinical Application for Recovery After Spinal Cord Injury. J Neurol Phys Ther. 2017;41 Suppl 3:S39&#x2013;S45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477660</ArticleId><ArticleId IdType="pubmed">28628595</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli CA, Boakye M, Morton RA, Vogt J, Benton K, Chen Y, et al. Recovery of Over-Ground Walking after Chronic Motor Complete Spinal Cord Injury. N Engl J Med. 2018;379(13):1244&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30247091</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JW, Becker D, Sadowsky CL, Jane JA, Conturo TE, Schultz LM. Late recovery following spinal cord injury. Case report and review of the literature. J Neurosurg. 2002;97(2 Suppl):252&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12296690</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobkin BH. Do electrically stimulated sensory inputs and movements lead to long-term plasticity and rehabilitation gains? Curr Opin Neurol. 2003;16(6):685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">14624077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghai S, Ghai I, Schmitz G, Effenberg AO. Effect of rhythmic auditory cueing on parkinsonian gait: A systematic review and meta-analysis. Sci Rep. 2018;8(1):506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764963</ArticleId><ArticleId IdType="pubmed">29323122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015;1(1):e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821084</ArticleId><ArticleId IdType="pubmed">27066542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman MC. Power of rare diseases: found in translation. Sci Transl Med. 2013;5(201):201ps11.</Citation><ArticleIdList><ArticleId IdType="pubmed">24005157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan JY, Meoded A, Danielian LE, Wu T, Floeter MK. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin. 2012;2:151&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778247</ArticleId><ArticleId IdType="pubmed">24179768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan JY, Jeong SY, Van Gelderen P, Deng HX, Quezado MM, Danielian LE, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One. 2012;7(4):e35241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328441</ArticleId><ArticleId IdType="pubmed">22529995</ArticleId></ArticleIdList></Reference><Reference><Citation>Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993;189(3):843&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8234713</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Alshikho MJ, Zurcher NR, Cernasov P, Babu S, Loggia ML, et al. Imaging of glia activation in people with primary lateral sclerosis. Neuroimage Clin. 2018;17:347&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681341</ArticleId><ArticleId IdType="pubmed">29159046</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Shytbel W, Murphy K, Hoirch M. Cortical magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve. 1990;13(2):146&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">2314418</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, Dharmadasa T, Vucic S, Kiernan MC. Functional Biomarkers for Amyotrophic Lateral Sclerosis. Front Neurol. 2018;9:1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328463</ArticleId><ArticleId IdType="pubmed">30662429</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Sue CM, Kumar KR, Ng K, Yiannikas C, et al. Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia. Eur J Neurol. 2015;22(5):826&#x2013;31, e57&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25683471</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistris MR, Rosler KM. The triple stimulation technique to study corticospinal conduction. Suppl Clin Neurophysiol. 2003;56:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14677379</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistris MR, Rosler KM, Truffert A, Landis T, Hess CW. A clinical study of motor evoked potentials using a triple stimulation technique. Brain. 1999;122 (Pt 2):265&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071055</ArticleId></ArticleIdList></Reference><Reference><Citation>Moise N, Wood D, Cheung YKK, Duan N, Onge TS, Duer-Hefele J, et al. Patient preferences for personalized (N-of-1) trials: a conjoint analysis. J Clin Epidemiol. 2018;102:12&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119511</ArticleId><ArticleId IdType="pubmed">29859242</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017;377(1):62&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28679092</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon R Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. Clin Pharmacol Ther. 2017;102(6):934&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">28795401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU Next Generation Alzheimer&#x2019;s prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814435</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25799162</ArticleId></ArticleIdList></Reference><Reference><Citation>Coalition APT. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462747</ArticleId></ArticleIdList></Reference><Reference><Citation>Janos T
Sean M
Healey &amp; AMG Center for ALS at Mass General receives &#x201c;May Proceed&#x201d; notice for three drugs in first ALS platform trial
2020.  [Available from: https://www.massgeneral.org/neurology/als/news/2020-01-22-Healey-ALS-platform-trial-may-proceed.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>